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Purpose: Elevated cyclic adenosine monophosphate (cAMP) enhances the barrier integrity of the corneal endothelium
and thereby facilitates stromal hydration control, which is necessary for corneal transparency. This study investigates
whether elevated cAMP is effective against the tumor necrosis factor-alpha (TNF-α)-induced loss of barrier integrity in
monolayers of bovine corneal endothelial cells (BCEC).
Methods: BCEC in primary culture were used for the study. Trans-endothelial electrical resistance (TER), a measure of
barrier integrity, was determined by electrical cell-substrate impedance sensing. The changes were also ascertained by
measuring paracellular permeability to fluorescein isothiocyanate (FITC)-dextran (10 kDa) across cells grown on porous
culture inserts, and by immunofluorescence imaging of the apical junctional complex (AJC). The activation of p38 MAP
kinase was assessed using western blotting.
Results: Co-treatment with forskolin, which activates adenylate cyclase, and rolipram, which inhibits cAMP-dependent
phosphodiesterase PDE4, reduced the TNF-α-induced increase in the flux of FITC-dextran. Similar co-treatment also
prevented the TNF-α-induced disorganization of zona occludens-1 (ZO-1) and cadherins at the AJC. Co-treatment, as
well pre-treatment, with forskolin plus rolipram prevented the TNF-α-induced decrease in TER. The influence of the
agents was significant after 12 h of exposure to the cytokine. This effect was also mimicked by A2B agonists, adenosine
and 5′-N-ethylcarboxamidoadenosine (NECA), which are known to mobilize cAMP in BCEC. Elevated cAMP also
inhibited the cytokine-induced activation of p38 MAP kinase, and further blocked the disassembly of microtubules as
well as the disruption of the PAMR (peri-junctional actomyosin ring) at the AJC.
Conclusions: These results suggest that elevated cAMP opposes the TNF-α-induced loss in barrier integrity of the corneal
endothelium. This effect follows inhibition of the cytokine-induced activation of p38 MAP kinase and its downstream
signaling involved in the disruption of AJC and PAMR, as well as the disassembly of microtubules.
Corneal transparency depends on stromal deturgescence,
which  is  maintained  by  the  ‘fluid  pump’  activity  of  its
posterior monolayer, the endothelium [1-4]. A major threat to
this  hydration  control  is  excessive  fluid  leakage  into  the
stroma, which may occur upon failure of the barrier integrity
associated with the endothelium. Situations involving barrier
dysfunction are known to occur in response to inflammatory
stress, such as during immune response secondary to allograft
rejection  [5-8],  anterior  uveitis  [9],  and  iatrogenic  injury
[10].  Tumor  necrosis  factor-alpha  (TNF-α)  is  a  pro-
inflammatory cytokine, the levels of which are significantly
elevated in the aqueous humor during allograft rejection [7]
and anterior uveitis [9]. A previous study by Watsky et al.
[11] involving rabbit corneas mounted in vitro demonstrated
that TNF-α breaks down the barrier integrity by disrupting the
actin cytoskeleton. This response to TNF-α was opposed by a
membrane-permeable  analog  of  cyclic  adenosine
monophosphate  (cAMP)  [11].  However,  the  mechanisms
underlying the disruption of the actin cytoskeleton by TNF-
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α  and  those  responsible  for  influencing  cAMP  were  not
elucidated.  It  would  be  useful  to  know  the  molecular
mechanisms involved in endothelial barrier dysfunction to
develop  pharmacological  strategies  to  overcome  stromal
edema during transplantation failure and uveitis.
Adenosine and forskolin, agents known to elevate cAMP
in the corneal endothelium, are known to promote stromal
deturgescence in rabbits [12]. Specifically, it has been shown
that these agents induce enhanced deswelling of preswollen
rabbit corneas by enhancing the barrier integrity rather than
by stimulating fluid transport [12,13]. In another study, rabbit
corneal endothelium exposed to rolipram, a selective inhibitor
of phosphodiesterase (isoform PDE4) [14], induced stromal
thinning [15]. In our previous studies, we demonstrated that
cAMP-induced myosin light chain (MLC) dephosphorylation
blocked the thrombin- and histamine-induced breakdown of
the  barrier  integrity  in  monolayers  of  bovine  corneal
endothelial cells (BCEC) [16-19]. In an analogous fashion,
the  breakdown  of  intercellular  communication  in  bovine
corneal  endothelium  in  response  to  increased  actomyosin
contractions is also suppressed by elevated cAMP [20-26]. In
addition  to  these  effects  of  the  second  messenger  on
containing  the  events  secondary  to  the  direct  increase  of
actomyosin contraction, our recent studies have focused on
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1781the influence of microtubule disassembly on the disruption of
the  actin  cytoskeleton  [27].  Thus,  nocadazole-induced
microtubule  disassembly  and  the  associated  increase  in
actomyosin contraction could also be inhibited by elevated
cAMP [27]. In a more recent study, we demonstrated that
TNF-α  induces  microtubule  disassembly  and  thereby
contributes to barrier failure in BCEC [28]. In a subsequent
study,  we  demonstrated  that  this  TNF-α  response  is
concomitant with the activation of p38 MAP kinase [29]. In
this study, we investigated the influence of elevated cAMP on
the  (TNF-α)-induced  barrier  dysfunction  in  BCEC  using
trans-endothelial electrical resistance (TER) as a principal
measure of barrier integrity. Our results show that agents that
elevate cAMP also oppose (TNF-α)-induced p38 MAP kinase
activation and thereby the loss of barrier function.
METHODS
Materials:  TNF-α  (biologic  activity  of  2×107  U/mg;
endotoxin  free),  forskolin,  adenosine,  5′-N-
ethylcarboxamidoadenosine (NECA), rolipram, pan-cadherin
antibody,  α-tubulin  antibody,  and  FITC-dextran  were
purchased from Sigma Aldrich (St. Louis, MO). Texas Red-
conjugated phalloidin, goat anti-mouse Alexa-488, and anti-
fade agent were purchased from Molecular Probes (Eugene,
OR). The ZO-1 antibody was procured from Zymed (Long
Island, NY). Electrodes (8W10E+) for TER measurements
were purchased from Applied Biophysics, Inc. (Troy, NY).
Tissue culture inserts (0.2 μm pore size) were obtained from
Nunc (Naperville, IL). The enhanced chemiluminescence kit
for  western  blotting  analysis  was  obtained  from  Thermo
Scientific (Rockford, IL).
Culture of bovine corneal endothelial cells: Primary cultures
of  BCEC  from  fresh  eyes  were  established  as  described
previously  [16-19].  The  growth  medium  contained
Dulbecco’s  Modified  Eagle's  Medium  (DMEM),
supplemented with 10% bovine calf serum and an antibiotic-
antimycotic  mixture  (penicillin,  100  U/ml,  streptomycin
100  μg/ml,  and  amphotericin-B  0.25  μg/ml).  Cells  were
cultured at 37 °C in a humidified atmosphere containing 5%
CO2. The medium was replaced every 2–3 days. Cells of the
first and second passages were harvested and seeded onto Petri
dishes and glass coverslips and allowed to grow to confluence
for  3–4  days  before  use.  Cell  culture  supplies  were  from
Invitrogen (Long Island, NY).
Immunocytochemistry: The components of the cytoskeleton
and apical junctional complex (AJC) were stained using an
immunocytochemistry  protocol,  as  described  previously
[27-31].  Cells  grown  on  coverslips  were  washed  with
phosphate buffer saline (PBS) after the desired drug treatment,
fixed with 3.7% paraformaldehyde and permeabilized using
0.2% Triton X-100 for 5 min. This was followed by staining
for F-actin using phalloidin conjugated to Texas Red (1:1,000)
for 45–60 min at room temperature (RT). Cells were stained
for microtubules, zona occludens-1 (ZO-1), and pan-cadherin
by fixing the cells, followed by permeabilization with 0.01%
saponin in PBS. The cells were exposed to a blocking buffer
for 45 min, and then incubated with the antibody for α-tubulin
(1:1,000)/ZO-1 (1:25)/pan-cadherin (1:1,000) in a mixture of
0.01% saponin in PBS-goat serum (1:1) overnight at 4 °C.
This  was  followed  by  washing  and  incubation  with  a
secondary antibody (goat anti-mouse IgG Alexa Fluor 488 at
1:1,000). Stained cells were mounted using anti-fade medium
containing 4',6-diamidino-2-phenylindole (DAPI), and then
visualized  using  an  epifluorescence  microscope  equipped
with  a  60×  oil  immersion  objective  and  1.2  NA  (Nikon,
Tokyo, Japan).
Trans-endothelial electrical resistance (TER): The TER was
measured  using  the  principle  of  electric  cell-substrate
impedance sensing using a commercial device (ECIS 1600R;
Applied Biophysics, Inc., Troy, NY), as described previously
[8,27-31]. Cells were seeded at a density of 5×105 cells/ml on
gold  electrodes  and  grown  to  confluence.  After  the
monolayers  showed  steady  resistance  values,  they  were
exposed to desired agents after at least 1 h exposure to serum-
free medium. The resistive portion of the measured impedance
(TER),  normalized  to  its  initial  value,  was  monitored
continuously and taken as a measure of barrier integrity.
Permeability to FITC-dextran: The changes in permeability
to FITC-dextran were determined by a protocol, as described
previously [27-31]. Cells were grown on 0.2 μm pore-size
collagen IV (1 mg/mL)-coated tissue culture inserts (Nunc™;
Fisher  Scientific,  Pittsburgh,  PA)  to  confluence.  The
monolayers were then serum-starved for 1 h and either left
untreated or exposed in triplicate to desired agents. Following
treatment, FITC-dextran (10 kDa), dissolved in Ringers, was
introduced in the apical compartment at a concentration of
0.4 μg/ml. After incubation at 37 °C for 2 h, samples were
taken  from  the  basolateral  chamber  for  fluorescence
measurements. Fluorescence was measured using excitation
at 492 nm and the emission was collected at 520 nm.
Western blot analysis: Confluent monolayers were serum-
starved overnight before treatment with desired agents. The
cells were then lysed with NP-40 lysis buffer (Invitrogen,
Carlsbad, CA) containing protease inhibitor cocktail (Sigma
Aldrich,  St.  Louis,  MO)  and  5×  reducing  sample  buffer
(Thermo  Scientific,  Rockford,  IL).  The  lysates  were
transferred to a microcentrifuge tube kept on ice, followed by
sonication  for  10–15  s.  The  lysates  were  centrifuged  at
14,000× g for 10 min followed by heating at 95–100 °C for 5
min.  The  samples  were  cooled  to  RT,  centrifuged,  and
resolved by electrophoresis. This was followed by transfer
onto  a  nitrocellulose  membrane  and  incubation  with  the
primary antibody (anti-phospho p38 MAP kinase; 1:1,000
dilution) overnight at 4 °C. The blots were washed with wash
buffer,  followed  by  incubation  with  HRP-conjugated
secondary antibody for 1 h at RT. The blots were visualized
using  an  enhanced  chemiluminescence  kit  (Thermo
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stripped of phospho-p38 antibody and probed for total p38
MAP kinase with the anti-p38 MAP kinase antibody (1:1,000
dilution).
Statistical analysis: Statistical comparisons were made using
one-way  ANOVA  (ANOVA)  with  Bonferroni’s  post-test
analysis  using  GraphPad  Prism  software  (Version  5.0;
GraphPad Software, Inc., San Diego, CA). A value of p<0.05
was considered statistically significant. Data are expressed as
mean ±SEM. The “n” represents the number of independent
experiments.
RESULTS
Effect of elevated cAMP on paracellular permeability: We
first examined the influence of cAMP on (TNF-α)-induced
increase  in  the  paracellular  permeability  to  FITC-dextran.
Exposure to 20 ng/ml of TNF-α for 20 h in the apical chamber
increased the flux of FITC-dextran by >8 fold when compared
to  untreated  cells  (Figure  1).  However,  co-treatment  with
10 μM forskolin and 50 μM rolipram opposed the cytokine-
induced increase in permeability.
Figure 1. Effect of elevated cAMP on barrier integrity. Changes in
paracellular permeability in response to TNF-α (20 ng/ml; T) with
or  without  co-treatment  with  10  µM  forskolin  (F)  and  50  µM
rolipram (R) were determined by quantifying the flux of FITC-
dextran  (10  kDa)  across  cells  grown  on  porous  culture  inserts.
Treatment with TNF-α for 20 h significantly increased the flux of
dextran in comparison to untreated cells (Control). Co-treatment with
F and R [i.e., TNF-α+F+R)] significantly attenuates the (TNF-α)-
induced increase in permeability. Each bar represents mean±SEM of
eight independent trials; * and ** denote p<0.001 when comparing
the TNF-α-treated group with the control group and the (TNF-α+F
+R)-treated group with the TNF-α-treated group, respectively.
Effect of elevated cAMP on the integrity of apical junctions:
The influence of TNF-α on the integrity of tight junctions
(TJs)  and  adherence  junctions  (AJs)  was  examined  by
immunostaining ZO-1 and cadherins as markers, respectively
[32,33].  In  untreated  cells,  the  distribution  of  ZO-1  and
cadherins is contiguous at the cell-cell borders, indicating
stable  TJs  and  AJs  (Figure  2A,E,  respectively).  Upon
treatment with forskolin and rolipram alone, the distribution
of ZO-1 and cadherins was undisturbed, similar to that of
untreated cells (Figure 2B,F, respectively). Co-treatment with
forskolin  and  rolipram  opposed  the  (TNF-α)-induced
dislocation of ZO-1 and the redistribution of cadherins (Figure
2C  versus  Figure  2D;  also  Figure  2G  versus  Figure  2H,
respectively). These findings are consistent with the effect of
elevated cAMP on the (TNF-α)-induced increase in FITC-
dextran permeability (Figure 1).
Effect of elevated cAMP on TER dynamics: To assess the
influence of elevated cAMP on TNF-α response at a higher
temporal resolution, we reexamined the barrier integrity in
terms of TER, as measured using the principle of electrical
cell-substrate impedance sensing [34]. As demonstrated in our
previous  studies  [28,29],  exposure  to  20  ng/ml  of  TNF-α
induced a decline in TER after a delay of about 2.5 h for more
than 20 h. However, pre-treatment with forskolin and rolipram
for 30 min opposed the reduction in TER (Figure 3A). Data
from independent experiments similar to that shown in Figure
3A are summarized in terms of percent reduction in TER at 4
h intervals after exposure to the cytokine (Figure 3B). It should
be noted that the pre-treatment with forskolin and rolipram
attenuated the (TNF-α)-induced decline in TER by >2 fold
after 12 h. Similarly, as shown in Figure 4, co-treatment of the
same drugs with TNF-α also opposed the TNF-α response by
about twofold. We also examined whether other agents known
to  elevate  cAMP  can  mimic  the  effect  of  forskolin.  Co-
treatment of NECA, (a potent A2B agonist) or adenosine (an
endogenous A2B agonist) with rolipram also attenuated the
(TNF-α)-induced decline in TER by about twofold (Figure 5A
and Figure 6A, respectively). As shown in Figure 5B and
Figure  6B,  the  effects  of  both  NECA  and  adenosine  are
significant after 12 h. These results demonstrate that elevated
cAMP opposes the loss of integrity of the endothelial barrier
induced by TNF-α.
Effect of elevated cAMP on the p38 MAP kinase activation:
Recently, we showed that p38 MAP kinase is activated in
response to TNF-α [29]. The activation peaked at 10 min and
its inhibition was found to effectively oppose the cytokine-
induced microtubule disassembly, as well as loss of barrier
function in BCEC [28]. Thus, we examined p38 MAP kinase
activation upon exposure to TNF-α with or without forskolin
and rolipram. As shown in Figure 7A, exposure to 20 ng/ml
of  TNF-α  for  10  min  induced  p38  MAP  kinase
phosphorylation. However, upon pretreatment with forskolin
and rolipram for 30 min, (TNF-α)-induced phosphorylation
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of similar experiments is shown in Figure 7B. It is clear that
elevated cAMP attenuates (TNF-α)-induced p38 MAP kinase
activation by about threefold at 10 min.
Effect of elevated cAMP on the cytoskeleton: In our previous
study  [29],  we  observed  that  (TNF-α)-induced  p38  MAP
kinase  activation  underlies  the  disruption  of  the  peri-
junctional  actomyosin  ring  (PAMR)  as  well  as  the
disassembly of the microtubules. Therefore, we examined
whether these responses are also blocked by elevated cAMP.
Figure 8 shows the influence of TNF-α on the organization of
microtubules and PAMR with and without co-treatment with
forskolin  and  rolipram.  In  untreated  cells  (Figure  8A),
microtubules extend from around the nucleus toward the cell
periphery as fibrillary structures. Treatment with 20 ng/ml
TNF-α for 6 h led to loss of the fibrillary extensions (Figure
8C). This loss is suppressed when cells are co-treated with
forskolin and rolipram (Figure 8D). Similarly, as shown in
Figure 8G, the (TNF-α)-induced disruption of the PAMR is
also opposed when cells are co-treated with forskolin and
rolipram (Figure 8H). Upon treatment with forskolin with
rolipram, the organization of microtubules (Figure 8B) as well
as PAMR (Figure 8F) was unaltered and similar to control.
These results indicate that elevated cAMP opposes the (TNF-
α)-induced  disruption  of  PAMR  as  well  as  microtubule
disassembly.
DISCUSSION
Corneal  endothelial  dysfunction  due  to  aging,  iatrogenic
injury,  Fuch’s  dystrophy,  and  inflammation  is  known  to
induce stromal edema leading to loss of acute vision [3,8].
Currently,  there  are  no  pharmacological  interventions  to
overcome the endothelial dysfunction, and the only recourse
is  corneal  transplantation.  However,  inflammatory  stress
during transplantation failure and uveitis is of concern [7,8,
11,35]. In this context, we investigated the role of TNF-α, a
prominent pro-inflammatory cytokine thought to play a major
role  in  corneal  endothelial  dysfunction  [7,8,11,35].  The
current  study  focused  on  the  role  of  barrier  dysfunction
induced by the cytokine and its modulation by cAMP. Our
major finding is that elevated cAMP attenuates the (TNF-α)-
induced barrier dysfunction by inhibiting p38 MAP kinase
activation.  Thus,  the  findings  of  this  study  suggest  it  is
possible to rescue corneas undergoing transplantation failure
or  challenged  by  anterior  uveitis  using  topical  agents
involving  cAMP-dependent  PDE  inhibitors  and/or  A2B
agonists, which can elevate cAMP in the corneal endothelium.
In our first study on TNF-α [28], we demonstrated that
the cytokine induces microtubule disassembly concomitant
with  loss  of  barrier  integrity  in  BCEC  monolayers.  In  a
subsequent study, we further showed that the cytokine effect
involves activation of p38 MAP kinase, which is a stress-
activated kinase [29]. Inhibition of p38 MAP kinase by its
selective  inhibitor  SB-203580  markedly  attenuated
microtubule disassembly. This is consistent with the loss of
Figure 2. Effect of elevated cAMP on the distribution of ZO-1 and cadherins. Cells were treated with TNF-α (T) for 6 h and where indicated
were co-treated with 10 µM forskolin (F) and 50 µM rolipram (R). A-D: Distribution of ZO-1. In untreated cells (Control, A), the ZO-1 is
contiguous at the cell-cell border (shown by arrows). It is undisturbed by F and R (B). Exposure to TNF-α (C) induced dispersion of ZO-1
(shown by arrows), which was opposed by co-treatment with F and R (D). E-H: Pan-cadherins at the focal plane of AJC. In untreated cells
(Control, E), localization of cadherins at the region of cell-cell contacts is intense (shown by arrows). Upon treatment with F and R (F), the
distribution of cadherins is unaltered. Exposure to TNF-α (G) resulted in reduced intensity of cadherins at the cell border as well as sporadic
disengagement (shown by arrows). Co-treatment with F and R (H) prevented the TNF-α response. All the images shown are representative
of at least three independent experiments.
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microtubule disassembly, as shown in our previous study with
BCEC [27]. The latter study [27] also demonstrated that the
loss of barrier integrity induced by microtubule disassembly
could  be  attenuated  by  co-treatment  with  forskolin  and
rolipram. Therefore, in this study, we began to investigate the
effect of elevated cAMP on the response to TNF-α.
In our first series of experiments, the barrier integrity was
assessed by following the flux of FITC-dextran. A nearly
eightfold increase in permeability to the dextran was reduced
to only twofold when cells were co-treated with forskolin and
rolipram (Figure 1). Since (TNF-α)-induced loss in barrier
integrity is not due to apoptosis, as shown in our previous
study [29], the observed effect of cAMP cannot be attributed
to cell survival. The effect of cAMP against the loss in barrier
integrity is also revealed by immunofluorescence of the AJC
complex (Figure 2). Specifically, the discontinuity in ZO-1
distribution  at  the  cell-cell  border  in  response  to  TNF-α
(Figure 2C) is not noticeable upon treatment with forskolin
and rolipram (Figure 2D). This is a clear indication of stable
TJs. The loss of AJs, evident because of the disassociation of
cadherins (Figure 2G) at the cell-cell border in response to the
Figure 3. Effect of forskolin plus rolipram pre-treatment on TER response. The changes in TER were measured in response to TNF-α (T) with
or without pre-treatment with 10 µM forskolin (F) and 50 µM rolipram (R) for 30 min. A: Typical responses. B: Summary of six independent
experiments. The % reduction in TER induced by the cytokine is significant when compared to control at >8 h. Pre-treatment with F and R
opposes the (TNF-α)-induced reduction in TER after 12 h of exposure. * and ** denotes p<0.001 when comparing the TNF-α-treated group
with the control group and the (TNF-α+F+R) -treated group with the TNF-α-treated group, respectively.
Figure 4. Effect of forskolin and rolipram co-treatment on TER dynamics. The changes in TER were measured in response to TNF-α (T) with
or without co-treatment with 10 µM forskolin (F) and 50 µM rolipram (R). A: Typical responses. B: Summary of six independent experiments.
The % reduction in TER induced by the cytokine is significant when compared to control at >8 h. Co-treatment with F and R opposes the
(TNF-α)-induced reduction in TER after 12 h of exposure. * and ** denotes p<0.001 when comparing the TNF-α-treated group with the
control group and the (TNF-α+F+R)-treated group with the TNF-α-treated group, respectively.
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Thus, both TJs and AJs, which are disrupted in response to
TNF-α, remain intact with elevated cAMP.
As shown in Figure 3A, Figure 4A, Figure 5A, and Figure
6A, TNF-α produced a steady decline in TER as expected.
When  cells  were  co-treated  with  forskolin,  NECA,  or
adenosine, the decline in TER was significantly attenuated.
The statistical summary in Figure 3B, Figure 4B, Figure 5B,
and Figure 6B gives clear evidence for the influence of cAMP-
elevating agents on the response to TNF-α. Specifically, each
of the agents reduced the loss in TER, and the reduction
became  statistically  significant  (p<0.001)  after  12  h  of
exposure to the cytokine. The apparent efficacy of NECA and
adenosine when compared to that of forskolin is consistent
with the reported activity of A2B receptors, which are coupled
to  Gs  G  protein,  in  the  corneal  endothelium  [16,18,36].
Previously, we showed that adenosine enhances intracellular
cAMP by 11-fold when compared to untreated cells [16].
Figure 5. Effect of NECA on TER dynamics. The changes in TER were measured in response to TNF-α (T) with or without co-treatment with
20 µM NECA (N) and 50 µM rolipram (R). A: Typical responses. B: Summary of six independent experiments. The % reduction in TER
induced by the cytokine is significant when compared to control at >8 h. Co-treatment with N and R opposes the TNF-α-induced reduction
in TER after 12 h of exposure. * and ** denote p<0.001 when comparing the TNF-α-treated group with the control group and the (TNF-α+N
+R)-treated group with the TNF-α-treated group, respectively.
Figure 6. Effect of adenosine on TER dynamics. The changes in TER were measured in response to TNF-α (T) with or without co-treatment
with 200 µM adenosine (A) and 50 µM rolipram (R). A: Typical responses. B: Summary of six independent experiments. The percent reduction
in TER induced by the cytokine is significant when compared to control at >8 h. Co-treatment with A and R opposes the TNF-α-induced
reduction in TER after 12 h of exposure. * and ** denote p<0.001 when comparing the TNF-α-treated group with the control group and the
(TNF-α+A+R)-treated group with the TNF-α-treated group, respectively.
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untreated cells (Figure 5A and Figure 6A). This is consistent
with  our  previous  measurements  of  impedance  with  cells
grown on porous filters [18]. Taken together, our findings in
Figure 1, Figure 2, Figure 3, Figure 4, Figure 5, and Figure 6
confirm that cAMP-elevating agents oppose the loss of barrier
integrity in response to TNF-α.
In our previous studies [28,29], we observed significant
influence of the cytokine on the actin cytoskeleton, similar to
what was observed by Watsky et al. [11] in rabbit corneal
endothelial cells. Specifically, we found that the cytokine
induces disassembly of microtubules [28], which in and of
itself is able to induce disruption of the PAMR, as shown by
our nocodazole study [27]. All these changes were opposed
by the inhibition of p38 MAP kinase [29]. As a distinct pool
of  F-actin  at  the  AJC,  the  PAMR  is  structurally  and
functionally  coupled  to  TJs  and  AJs  [8].  Upon  excessive
actomyosin contraction of the PAMR, the centripetal force
generated around AJC reduces cell-cell tethering and this
opposes the stable interaction of trans-membrane domains of
the TJs and AJs [8,30]. In light of these observations, we
examined whether the influence of cAMP-elevating agents
also manifested at the level of the cytoskeleton. In all our
experiments, in agreement with the containment of loss of
barrier integrity, forskolin and rolipram conferred protection
against the (TNF-α)-induced microtubule disassembly and
disruption of the PAMR (Figure 8).
Although (TNF-α)-induced barrier dysfunction has been
widely examined [11,37,38], the ability of cAMP-elevating
agents to counter the influence of the cytokine has not received
much  attention  [39,40].  One  can  find  several  reasons,
however, for employing agents that elevate cAMP to oppose
the response to TNF-α. First, the second messenger is tightly
coupled to the regulation of the actin cytoskeleton by cross-
talk between the RhoA-Rho kinase axis as well as Rac1-
dependent  mechanisms  [41-43].  Second,  TNF-α  has  been
shown  to  elicit  upregulation  of  cAMP-dependent
phosphodiesterases [40]. Although the RhoA-Rho kinase axis
is implicated in TNF-α signaling [44], there are no reports
showing the efficacy of Rho kinase inhibitors against the loss
of  barrier  integrity  induced  by  the  cytokine.  Thus,
mechanisms  involved  in  the  disruption  of  the  actin
cytoskeleton  appear  to  be  significantly  influenced  by
pathways independent of the RhoA-Rho kinase axis.
The other major mechanisms implicated in the response
to TNF-α include activation of ROS/RNS (reactive oxygen/
nitrogen species) [45-47], stress kinases [38,48], microtubule
disassembly [38,49], and transcriptional activation of genes
Figure 7. Effect of elevated cAMP on
p38 MAP kinase activation. p38 MAP
kinase activation following exposure to
20 ng/ml TNF-α (T) for 10 min with or
without  pre-treatment  with  10  µM
forskolin (F) and 50 µM rolipram (R) for
30  min  was  confirmed  by
immunoblotting  using  both  anti-
phospho-specific  p38  MAP  kinase
antibody  and  anti-p38  MAP  kinase
antibody.  A:  TNF-α-induced
phosphorylation  of  p38  MAP  kinase
following  10  min  of  exposure.
However, pre-treatment with forskolin
(F)  and  rolipram  (R)  suppressed  p38
MAP  kinase  phosphorylation  induced
by  TNF-α  (T).  B:  Bar  graph  of  the
densitometric  analysis  of  three
independent experiments similar to that
shown in A. The ratio of phosphorylated
to total p38 MAP kinase following TNF-
α stimulation is significantly increased
when compared to untreated cells. Pre-
treatment  with  F  and  R  followed  by
stimulation  with  TNF-α  significantly
decreases the ratio. * and ** denotes
p<0.001 when comparing the TNF-α-
treated group with the control group and
the  (TNF-α+F+R)-treated  group  with
the TNF-α-treated group, respectively.
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1787that might influence the actin cytoskeleton, including myosin
light chain kinase (MLCK) [44,50] and heat shock protein 27
(Hsp27) [51]. As previously noted, we earlier demonstrated a
major role for p38 MAP kinase and microtubule disassembly
in the response to TNF-α [28,29]. Although the underlying
molecular  mechanisms  are  unknown,  it  appears  that  the
microtubule disassembly follows p38 MAP kinase activation
[52,53]. Thus, inhibition of the kinase attenuated the cytokine-
induced  microtubule  disassembly.  These  observations  are
similar to findings in pulmonary vascular endothelial cells
[38]. As shown in Figure 7, the (TNF-α)-induced activation
of p38 MAP kinase is markedly reduced upon pre-treatment
with forskolin and rolipram, suggesting that the influence of
cAMP  could  be  due  to  regulation  of  the  kinase  itself.
Consistent with this finding, a recent study in HeLa cells and
fibroblasts  showed  that  cAMP  may  act  through  the
transcription factor CREB to bring about the expression of
dynein light chain (DLC), which disrupted the formation of
the  MKK3/6-p38  complex  upstream  of  p38  MAP  kinase
[54]. Increased cAMP in vascular endothelial cells has been
shown  to  prevent  thrombin-induced  intracellular  adhesion
molecule (ICAM)-1 expression by inhibiting p38 MAP kinase
activation [55]. These reports are in line with the effect of
elevated cAMP on the inhibition of (TNF-α)-induced p38
MAP kinase activation, shown in Figure 7.
In conclusion, we have demonstrated for the first time
that elevated cAMP opposes p38 MAP kinase activation by
TNF-α, and thereby attenuates downstream events leading to
barrier  dysfunction  in  the  corneal  endothelium.  Hence,
elevation of cAMP can be a therapeutic strategy to overcome
endothelial barrier dysfunction in response to TNF-α during
corneal transplantation failure and/or uveitis.
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